Zacks Research Brokers Raise Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Zacks Research increased their Q2 2025 earnings estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.62 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ FY2025 earnings at $2.43 EPS and Q1 2026 earnings at $0.67 EPS.

EW has been the topic of a number of other research reports. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. UBS Group dropped their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Barclays raised their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $78.65.

Edwards Lifesciences Price Performance

Shares of EW opened at $73.32 on Monday. The firm’s fifty day simple moving average is $69.42 and its 200-day simple moving average is $73.90. The firm has a market capitalization of $43.24 billion, a price-to-earnings ratio of 10.58, a PEG ratio of 3.63 and a beta of 1.12. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,000 shares of company stock worth $2,323,150. 1.29% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after acquiring an additional 40,348 shares during the last quarter. AIA Group Ltd increased its stake in shares of Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after purchasing an additional 358,556 shares during the last quarter. RiverPark Advisors LLC raised its holdings in shares of Edwards Lifesciences by 58.1% during the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock valued at $1,362,000 after purchasing an additional 7,583 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in shares of Edwards Lifesciences by 40.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company’s stock valued at $3,394,000 after purchasing an additional 10,492 shares during the last quarter. Finally, Banque Cantonale Vaudoise boosted its holdings in Edwards Lifesciences by 46.9% in the third quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock worth $5,353,000 after purchasing an additional 25,886 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.